Newsflash: The Dividend Aristocrats Found The Lost Decade
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »|
Price
$20.35
|
Market Cap
134.2M
|
Sector
Health Care
|
Div. Growth
-
|
|
P/E
20.9
|
P/B
1.46
|
P/S
0.48
|
Dividend %
-
|
|
P/CF
308.3
|
P/FCF
10.9
|
Op. Cash Flow
13.4
|
FCF/Share
1.1
|
|
Op. Margin
4.00%
|
Net Margin
2.30%
|
ROE
7.30%
|
ROI
-1.40%
|
|
ROA
4.20%
|
EPS Growth
314.30%
|
Curr. Ratio
2.1
|
Debt/Equity
28.9
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Escalon Medical Corp. (ESMC) | $1.30 | - | - | 7.8M | |
| China Pharmaceuticals, Inc. (CFMI) | $0.02 | - | - | 800K | |
| Merus Labs International Inc ( (MSLI) | $0.80 | - | - | 19.6M | |
| Centene Corp (CNC) | $51.98 | - | - | 2.57B | |
| MGC Diagnostics Corp (MGCD) | $7.82 | - | - | 29M |
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »I'm inspired to write this article because I am so frustrated by the plethora of all the so-called expert market prognosticators that continuously bombard the public with negative forecasts.
Read more »One of the great long-term benefits that a recession brings is the opportunity to invest in extremely high-quality companies at low valuations.
Read more »
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
